Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

NIH division awards $2.5M for PET-based Alzheimer's research

The National Institute on Aging awarded Wake Forest School of Medicine a five-year grant to examine if a novel PET tracer can help researchers tackle the disease.

Thumbnail

Brain PET research at critical ‘crossroads,' must move toward collaboration to advance

Nuclear medicine experts called on the field to work together and share data in order to produce the sample sizes needed for further breakthroughs.

Thumbnail

FDA approves PET tracer trial testing ability to diagnose multiple sclerosis

The imaging agent—Myeliviz—will be tested in humans for the first time, and may change the way clinicians diagnose the autoimmune disease.

Thumbnail

PET/MRI spots breast cancer biomarkers for risk-based screening methods

Imaging markers such as breast parenchymal uptake varied greatly between women with benign and malignant lesions, according to a study published in the Journal of Nuclear Medicine.

Thumbnail

US waives ban on uranium exports used to produce Mo-99

The move delays a restriction on licenses required to export highly enriched uranium for two years.

Thumbnail

PET tracer can help fight heart attacks earlier in the process

Researchers may improve heart attack outcomes by zeroing in on the cellular activity that causes long-lasting damage to the heart.

Thumbnail

Tau PET imaging beats amyloid-based approach in battle against Alzheimer’s

Amyloid plaques have long been the target of Alzheimer’s-focused research, but a new study suggests it may be time to prioritize tau imaging instead.

Thumbnail

FDA approves PET imaging agent to fight Parkinson’s

The go-ahead was granted to the Feinstein Institutes for Medical Research to use Fluorodopa F-18 injections in patients with suspected Parkinson’s syndromes.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

Trimed Popup
Trimed Popup